Aleniglipron
Sources
registry, as of 2026-08-10Stale
https://clinicaltrials.gov/study/NCT07654361
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1). Overall status RECRUITING. Phases PHASE3. Lead sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Enrollment 3600. Conditions Obesity; Overweight; Chronic Weight Management. Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination
ClinicalTrials.gov NCT07654361 protocol and results modules
registry, as of 2026-10-20Stale
https://clinicaltrials.gov/study/NCT07654374
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2). Overall status RECRUITING. Phases PHASE3. Lead sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Enrollment 1100. Conditions Obesity; Overweight; Chronic Weight Management; Type2 Diabetes Mellitus. This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 7
ClinicalTrials.gov NCT07654374 protocol and results modules
registry, as of 2026-08-10Stale
https://clinicaltrials.gov/study/NCT06693843
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity. Overall status COMPLETED. Phases PHASE2. Lead sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Enrollment 230. Conditions Obesity, Overweight, or Chronic Weight Management. This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at least one weight-related comorbidity. Participants
ClinicalTrials.gov NCT06693843 protocol and results modules
registry, as of 2024-04-25Stale
https://clinicaltrials.gov/study/NCT05762471
Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Enrollment 142. Conditions Overweight or Obesity; Type2 Diabetes Mellitus. This study will evaluate safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects on GSBR-1290 in healthy overweight/obese volunteers (HOV) and Type 2 Diabetes Mellitus on Metformin (T2DM) This study includes 5 planned cohorts. Participants will receiv
ClinicalTrials.gov NCT05762471 protocol and results modules
registry, as of 2026-04-28Stale
https://clinicaltrials.gov/study/NCT06703021
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity. Overall status COMPLETED. Phases PHASE2. Lead sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Enrollment 85. Conditions Obesity; Overweight; Chronic Weight Management. Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet an
ClinicalTrials.gov NCT06703021 protocol and results modules
registry, as of 2026-10-14Stale
https://clinicaltrials.gov/study/NCT07169942
Aleniglipron Phase 2 Body Composition Study. Overall status COMPLETED. Phases PHASE2. Lead sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Enrollment 71. Conditions Obesity, Overweight, or Chronic Weight Management. This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending
ClinicalTrials.gov NCT07169942 protocol and results modules
registry, as of 2026-10-21Stale
https://clinicaltrials.gov/study/NCT07400588
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus. Overall status COMPLETED. Phases PHASE2. Lead sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Enrollment 58. Conditions Obese; Obesity; Obesity Type 2 Diabetes Mellitus; Weight Loss. The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 180 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2).
ClinicalTrials.gov NCT07400588 protocol and results modules
registry, as of 2024-02-15Stale
https://clinicaltrials.gov/study/NCT06139055
A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants. Overall status UNKNOWN. Phases PHASE1. Lead sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Enrollment 70. Conditions Healthy Volunteers. The purpose of this study is to compare the safety, tolerability, pharmacokinetic (PK), and comparative bioavailability of repeated administration of GSBR-1290 in healthy overweight/obese participants.
ClinicalTrials.gov NCT06139055 protocol and results modules
publication, as of 2026-08-14Stale
https://pubmed.ncbi.nlm.nih.gov/42249138/
randomized, double-blind, placebo-controlled phase 2b trial. Aleniglipron is an oral, small-molecule glucagon-like peptide-1 receptor agonist (GLP1-RA) in development for obesity treatment. The ACCESS phase 2b placebo-controlled, double-blind study randomized 230 adults (mean BMI 39.5 kg m -2 , 54% female) with o
PMID 42249138